H3F3A is an inclusion criterion in 7 clinical trials for diffuse midline glioma, H3 K27M-mutant, of which 7 are open and 0 are closed. Of the trials that contain H3F3A status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 5 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

H3F3A is an inclusion criterion in 6 clinical trials for diffuse intrinsic pontine glioma, of which 6 are open and 0 are closed. Of the trials that contain H3F3A status and diffuse intrinsic pontine glioma as inclusion criteria, 4 are phase 1 (4 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 3 (1 open) [4].

H3F3A is an inclusion criterion in 4 clinical trials for malignant glioma, of which 4 are open and 0 are closed. Of the trials that contain H3F3A status and malignant glioma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 2 (1 open) [4].

H3F3A is an inclusion criterion in 3 clinical trials for anaplastic astrocytoma, of which 3 are open and 0 are closed. Of the trials that contain H3F3A status and anaplastic astrocytoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 3 (1 open) [4].

H3F3A is an inclusion criterion in 3 clinical trials for atypical teratoid/rhabdoid tumor, of which 3 are open and 0 are closed. Of the trials that contain H3F3A status and atypical teratoid/rhabdoid tumor as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [4].

H3F3A is an inclusion criterion in 3 clinical trials for diffuse glioma, of which 3 are open and 0 are closed. Of the trials that contain H3F3A status and diffuse glioma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 3 (1 open) [4].

H3F3A is an inclusion criterion in 3 clinical trials for ependymoma, of which 3 are open and 0 are closed. Of the trials that contain H3F3A status and ependymoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [4].

H3F3A is an inclusion criterion in 3 clinical trials for glioblastoma, of which 3 are open and 0 are closed. Of the trials that contain H3F3A status and glioblastoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 3 (1 open) [4].

H3F3A is an inclusion criterion in 3 clinical trials for glioma, of which 3 are open and 0 are closed. Of the trials that contain H3F3A status and glioma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

H3F3A is an inclusion criterion in 3 clinical trials for medulloblastoma, of which 3 are open and 0 are closed. Of the trials that contain H3F3A status and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [4].

H3F3A is an inclusion criterion in 2 clinical trials for anaplastic pleomorphic xanthoastrocytoma, of which 2 are open and 0 are closed. Of the trials that contain H3F3A status and anaplastic pleomorphic xanthoastrocytoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

H3F3A is an inclusion criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain H3F3A status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

H3F3A is an inclusion criterion in 2 clinical trials for embryonal tumor with multilayered rosettes, C19MC-altered, of which 2 are open and 0 are closed. Of the trials that contain H3F3A status and embryonal tumor with multilayered rosettes, C19MC-altered as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

H3F3A is an inclusion criterion in 2 clinical trials for embryonal tumor with multilayered rosettes, not otherwise specified, of which 2 are open and 0 are closed. Of the trials that contain H3F3A status and embryonal tumor with multilayered rosettes, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

H3F3A is an inclusion criterion in 2 clinical trials for gliomatosis cerebri, of which 2 are open and 0 are closed. Of the trials that contain H3F3A status and gliomatosis cerebri as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 3 (1 open) [4].

H3F3A is an inclusion criterion in 2 clinical trials for gliosarcoma, of which 2 are open and 0 are closed. Of the trials that contain H3F3A status and gliosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

H3F3A is an inclusion criterion in 2 clinical trials for high-grade glioma, NOS, of which 2 are open and 0 are closed. Of the trials that contain H3F3A status and high-grade glioma, NOS as inclusion criteria, 2 are phase 1 (2 open) [4].

H3F3A is an inclusion criterion in 2 clinical trials for primitive neuroectodermal tumor, of which 2 are open and 0 are closed. Of the trials that contain H3F3A status and primitive neuroectodermal tumor as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

H3F3A is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, IDH-mutant, of which 1 is open and 0 are closed. Of the trial that contains H3F3A status and anaplastic astrocytoma, IDH-mutant as inclusion criteria, 1 is phase 1 (1 open) [4].

H3F3A is an inclusion criterion in 1 clinical trial for anaplastic ependymoma, of which 1 is open and 0 are closed. Of the trial that contains H3F3A status and anaplastic ependymoma as inclusion criteria, 1 is phase 1 (1 open) [4].

H3F3A is an inclusion criterion in 1 clinical trial for anaplastic oligoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains H3F3A status and anaplastic oligoastrocytoma as inclusion criteria, 1 is phase 1 (1 open) [4].

H3F3A is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains H3F3A status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [4].

H3F3A is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted, of which 1 is open and 0 are closed. Of the trial that contains H3F3A status and anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted as inclusion criteria, 1 is phase 1 (1 open) [4].

H3F3A is an inclusion criterion in 1 clinical trial for atypical meningioma, of which 1 is open and 0 are closed. Of the trial that contains H3F3A status and atypical meningioma as inclusion criteria, 1 is phase 2 (1 open) [4].

H3F3A is an inclusion criterion in 1 clinical trial for central nervous system ganglioneuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains H3F3A status and central nervous system ganglioneuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [4].

H3F3A is an inclusion criterion in 1 clinical trial for central nervous system neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains H3F3A status and central nervous system neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [4].

H3F3A is an inclusion criterion in 1 clinical trial for central nervous system sarcoma, of which 1 is open and 0 are closed. Of the trial that contains H3F3A status and central nervous system sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

H3F3A is an inclusion criterion in 1 clinical trial for choroid plexus neoplasm, of which 1 is open and 0 are closed. Of the trial that contains H3F3A status and choroid plexus neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

H3F3A is an inclusion criterion in 1 clinical trial for ependymal tumor, of which 1 is open and 0 are closed. Of the trial that contains H3F3A status and ependymal tumor as inclusion criteria, 1 is phase 1 (1 open) [4].

H3F3A is an inclusion criterion in 1 clinical trial for ependymoma, RELA fusion-positive, of which 1 is open and 0 are closed. Of the trial that contains H3F3A status and ependymoma, RELA fusion-positive as inclusion criteria, 1 is phase 1 (1 open) [4].

H3F3A is an inclusion criterion in 1 clinical trial for fibrillary astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains H3F3A status and fibrillary astrocytoma as inclusion criteria, 1 is phase 1 (1 open) [4].

H3F3A is an inclusion criterion in 1 clinical trial for malignant central nervous system germ cell tumor, of which 1 is open and 0 are closed. Of the trial that contains H3F3A status and malignant central nervous system germ cell tumor as inclusion criteria, 1 is phase 1 (1 open) [4].

H3F3A is an inclusion criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains H3F3A status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].

H3F3A is an inclusion criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains H3F3A status and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 2 (1 open) [4].

H3F3A is an inclusion criterion in 1 clinical trial for malignant primary brain neoplasm, of which 1 is open and 0 are closed. Of the trial that contains H3F3A status and malignant primary brain neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].

H3F3A is an inclusion criterion in 1 clinical trial for medulloblastoma, non-WNT/non-SHH, of which 1 is open and 0 are closed. Of the trial that contains H3F3A status and medulloblastoma, non-WNT/non-SHH as inclusion criteria, 1 is phase 1 (1 open) [4].

H3F3A is an inclusion criterion in 1 clinical trial for medulloblastoma, SHH-activated, of which 1 is open and 0 are closed. Of the trial that contains H3F3A status and medulloblastoma, SHH-activated as inclusion criteria, 1 is phase 1 (1 open) [4].

H3F3A is an inclusion criterion in 1 clinical trial for medulloblastoma, WNT-activated, of which 1 is open and 0 are closed. Of the trial that contains H3F3A status and medulloblastoma, WNT-activated as inclusion criteria, 1 is phase 1 (1 open) [4].

H3F3A is an inclusion criterion in 1 clinical trial for medulloepithelioma, of which 1 is open and 0 are closed. Of the trial that contains H3F3A status and medulloepithelioma as inclusion criteria, 1 is phase 1 (1 open) [4].

H3F3A is an inclusion criterion in 1 clinical trial for pineal region neoplasm, of which 1 is open and 0 are closed. Of the trial that contains H3F3A status and pineal region neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

H3F3A is an inclusion criterion in 1 clinical trial for pineoblastoma, of which 1 is open and 0 are closed. Of the trial that contains H3F3A status and pineoblastoma as inclusion criteria, 1 is phase 2 (1 open) [4].

H3F3A is an inclusion criterion in 1 clinical trial for pineocytoma, of which 1 is open and 0 are closed. Of the trial that contains H3F3A status and pineocytoma as inclusion criteria, 1 is phase 2 (1 open) [4].

H3F3A is an inclusion criterion in 1 clinical trial for pleomorphic xanthoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains H3F3A status and pleomorphic xanthoastrocytoma as inclusion criteria, 1 is phase 2 (1 open) [4].